David B Olawade, Jennifer Teke, Khadijat K Adeleye, Eghosasere Egbon, Kusal Weerasinghe, Saak V Ovsepian, Stergios Boussios
{"title":"为并发偏头痛患者提供人工智能引导的癌症疗法。","authors":"David B Olawade, Jennifer Teke, Khadijat K Adeleye, Eghosasere Egbon, Kusal Weerasinghe, Saak V Ovsepian, Stergios Boussios","doi":"10.3390/cancers16213690","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Cancer remains a leading cause of death worldwide. Progress in its effective treatment has been hampered by challenges in personalized therapy, particularly in patients with comorbid conditions. The integration of artificial intelligence (AI) into patient profiling offers a promising approach to enhancing individualized anticancer therapy. <b>Objective</b>: This narrative review explores the role of AI in refining anticancer therapy through personalized profiling, with a specific focus on cancer patients with comorbid migraine. <b>Methods</b>: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar. Studies were selected based on their relevance to AI applications in oncology and migraine management, with a focus on personalized medicine and predictive modeling. Key themes were synthesized to provide an overview of recent developments, challenges, and emerging directions. <b>Results</b>: AI technologies, such as machine learning (ML), deep learning (DL), and natural language processing (NLP), have become instrumental in the discovery of genetic and molecular biomarkers of cancer and migraine. These technologies also enable predictive analytics for assessing the impact of migraine on cancer therapy in comorbid cases, predicting outcomes and provide clinical decision support systems (CDSS) for real-time treatment adjustments. <b>Conclusions</b>: AI holds significant potential to improve the precision and effectiveness of the management and therapy of cancer patients with comorbid migraine. Nevertheless, challenges remain over data integration, clinical validation, and ethical consideration, which must be addressed to appreciate the full potential for the approach outlined herein.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 21","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544931/pdf/","citationCount":"0","resultStr":"{\"title\":\"AI-Guided Cancer Therapy for Patients with Coexisting Migraines.\",\"authors\":\"David B Olawade, Jennifer Teke, Khadijat K Adeleye, Eghosasere Egbon, Kusal Weerasinghe, Saak V Ovsepian, Stergios Boussios\",\"doi\":\"10.3390/cancers16213690\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background</b>: Cancer remains a leading cause of death worldwide. Progress in its effective treatment has been hampered by challenges in personalized therapy, particularly in patients with comorbid conditions. The integration of artificial intelligence (AI) into patient profiling offers a promising approach to enhancing individualized anticancer therapy. <b>Objective</b>: This narrative review explores the role of AI in refining anticancer therapy through personalized profiling, with a specific focus on cancer patients with comorbid migraine. <b>Methods</b>: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar. Studies were selected based on their relevance to AI applications in oncology and migraine management, with a focus on personalized medicine and predictive modeling. Key themes were synthesized to provide an overview of recent developments, challenges, and emerging directions. <b>Results</b>: AI technologies, such as machine learning (ML), deep learning (DL), and natural language processing (NLP), have become instrumental in the discovery of genetic and molecular biomarkers of cancer and migraine. These technologies also enable predictive analytics for assessing the impact of migraine on cancer therapy in comorbid cases, predicting outcomes and provide clinical decision support systems (CDSS) for real-time treatment adjustments. <b>Conclusions</b>: AI holds significant potential to improve the precision and effectiveness of the management and therapy of cancer patients with comorbid migraine. Nevertheless, challenges remain over data integration, clinical validation, and ethical consideration, which must be addressed to appreciate the full potential for the approach outlined herein.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"16 21\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544931/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers16213690\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16213690","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:癌症仍然是全球死亡的主要原因。由于个性化治疗面临挑战,特别是对合并症患者的治疗,阻碍了有效治疗癌症的进展。将人工智能(AI)整合到患者特征描述中,为加强个体化抗癌治疗提供了一种前景广阔的方法。目的:这篇叙述性综述探讨了人工智能在通过个性化分析完善抗癌疗法中的作用,并特别关注合并偏头痛的癌症患者。研究方法在多个数据库(包括 PubMed、Scopus 和 Google Scholar)中进行了全面的文献检索。根据研究与人工智能在肿瘤学和偏头痛管理中的应用的相关性选择研究,重点关注个性化医疗和预测建模。对关键主题进行了综合,以概述最新发展、挑战和新兴方向。成果:机器学习 (ML)、深度学习 (DL) 和自然语言处理 (NLP) 等人工智能技术在发现癌症和偏头痛的基因和分子生物标记物方面发挥了重要作用。这些技术还能进行预测分析,评估偏头痛对合并癌症治疗的影响,预测结果,并提供临床决策支持系统(CDSS)以进行实时治疗调整。结论人工智能在提高合并偏头痛的癌症患者的管理和治疗的精确性和有效性方面具有巨大潜力。然而,数据整合、临床验证和伦理考虑等方面的挑战依然存在,必须解决这些问题,才能充分发挥本文所述方法的潜力。
AI-Guided Cancer Therapy for Patients with Coexisting Migraines.
Background: Cancer remains a leading cause of death worldwide. Progress in its effective treatment has been hampered by challenges in personalized therapy, particularly in patients with comorbid conditions. The integration of artificial intelligence (AI) into patient profiling offers a promising approach to enhancing individualized anticancer therapy. Objective: This narrative review explores the role of AI in refining anticancer therapy through personalized profiling, with a specific focus on cancer patients with comorbid migraine. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar. Studies were selected based on their relevance to AI applications in oncology and migraine management, with a focus on personalized medicine and predictive modeling. Key themes were synthesized to provide an overview of recent developments, challenges, and emerging directions. Results: AI technologies, such as machine learning (ML), deep learning (DL), and natural language processing (NLP), have become instrumental in the discovery of genetic and molecular biomarkers of cancer and migraine. These technologies also enable predictive analytics for assessing the impact of migraine on cancer therapy in comorbid cases, predicting outcomes and provide clinical decision support systems (CDSS) for real-time treatment adjustments. Conclusions: AI holds significant potential to improve the precision and effectiveness of the management and therapy of cancer patients with comorbid migraine. Nevertheless, challenges remain over data integration, clinical validation, and ethical consideration, which must be addressed to appreciate the full potential for the approach outlined herein.
期刊介绍:
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.